Liquid Biopsy of Breast Cancer Update with Founder of Savran Tech.

<p>Sponsored by:</p> <ul> <li>Purdue University entrepreneurship</li> <li>Peter Fasse, patent attorney at Fish & Richardson</li> </ul> <p>In December of 2017 I interviewed Çağrı Savran, Ph.D. about plans for his startup in which I had just invested. Almost four years later I interviewed him again to review the progress of the company which is changing the way breast cancer is followed up after treatment.</p> <p>Highlights:</p> <ul> <li>Update on the Original Interview with Çağrı Savran, Ph.D.</li> <li>In December of 2017 Savran Was Operating with Essential Components Handmade in the Lab – In October 2021 the Main Components Are Produced by a Vendor</li> <li>Early Technology Was Used in a Major Clinical Trial at Indiana University School of Medicine and Significantly Improved Prediction of Recurrence of a Breast Cancer</li> <li>The Existing Technology for Capturing Circulating Tumor Cells Is Not Scalable – Savran’s Tech Is Amenable to Scale</li> <li>Strategic Players in Prenatal Diagnostics Are Interested in Sequencing the Cells Captured – Savran Is Uniquely Positioned to Provide That Ability</li> <li>The Basic Technology Is Like a Kitchen, the Different Assays Are Like What’s Being Prepared in the Kitchen</li> <li>Savran Has Recruited a Capable and Involved Board</li> <li>Sal Daher Summarizes Savran’s Progress in the Last Four Years</li> </ul>